IBCN 2022: Genome-Wide Circulating Tumor DNA for Monitoring Treatment Response and Metastatic Relapse in Bladder Cancer
Presented by Iver Nordentoft, MSc, PhD,
In this study presented by Dr. Nordentoft, a whole-genome sequencing (WGS) approach to circulating tumor DNA (ctDNA) was applied for sensitive monitoring of Minimal Residual Disease (MRD).
Read More
ESMO 2022: Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?
Presented by Rana McKay, MD
(UroToday.com) The 2022 ESMO annual meeting featured a urothelial carcinoma session, including a discussant presentation by Dr. Rana McKay discussing biomarkers for advanced urothelial carcinoma. Dr. McKay discussed two abstracts including “Genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma.
Read More
ASCO 2022: Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma
Presented by Jonathan E. Rosenberg, MD
Dr. Jonathan E. Rosenberg presented long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial.
Read More
ASCO 2022: Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17
At the 2022 ASCO annual meeting, the poster discussion session that focused on Kidney and Bladder cancers included a presentation from Dr. Richard Cathomas discussing the role of peri-operative chemoimmunotherapy for patients undergoing radical cystectomy for muscle invasive urothelial carcinoma based on the SAKK 06/17 trial.
Read More
ASCO 2022: Long-Term Outcomes in Patients with Advanced Urothelial Carcinoma (UC) Who Received Avelumab First-Line Maintenance with or Without Second-Line Treatment: Exploratory Analyses from JAVELIN Bladder 100
Presented by Joaquim Bellmunt, MD, PhD
At the 2022 American Society of Clinical Oncology Annual Meeting, Dr. Joaquim Bellmunt presented long-term outcomes from the JAVELIN Bladder 100 trial among patients receiving first-line avelumab maintenance therapy, with a specific focus on the use of subsequent second-line therapy.
Read More
ASCO 2022: Results From Cohorts 3, 4, 5 of the COSMIC-021 Study - Cabozantinib in Combination With Atezolizumab in Urothelial Carcinoma
Presented by Sumanta K. Pal, MD
In this presentation, Dr. Pal presented results from cohorts 3, 4 and 5 of COSMIC-021. In these cohorts, patients with locally advanced or metastatic transitional cell urothelial carcinoma who were ineligible for surgery were treated with cabozantinib and atezolizumab.
Read More
ASCO 2022: Cabozantinib in Combination with Atezolizumab in Urothelial Carcinoma: Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
Presented by Sumanta K. Pal, MD
The 2022 ASCO annual meeting featured an oral abstract session on kidney and bladder cancer, including a presentation by Dr. Monty Pal discussing results of cohorts 3, 4, and 5 in the COSMIC-021 study assessing cabozantinib + atezolizumab in urothelial carcinoma. Cabozantinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), promotes an immune-permissive environment that may enhance response to immune checkpoint inhibitors.
Read More
ASCO GU 2022: Discussion on the ATLANTIS and BAYOU Trials in Advanced Urothelial Cancer
Presented by Sandy Srinivas, MD
(UroToday.com) In an oral abstract presentation on the first day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022Dr. Heath provided a discussion following presentations from Dr. Crabb and Dr. Rosenberg on the ATLANTIS and BAYOU trials, respectively.
Read More
ASCO GU 2022: Study EV-302: A Two-Arm, Open-Label, Randomized Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Previously Untreated Advanced Urothelial Carcinoma
Presented by Michiel Simon Van Der Heijden MD, PhD
On the second day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022 focused on urothelial carcinoma during the Trials in Progress Poster Session B, Dr. Van Der Heijden presented the rationale and design of EV-302 assessing enfortumab vedotin (EV) with pembrolizumab compared to chemotherapy as first-line treatment in advanced urothelial carcinoma (aUC).
Read More
ASCO GU 2022: BAYOU: A Phase II, Randomized, Multicenter, Double-Blind, Study of Durvalumab in Combination With Olaparib for the First-Line Treatment of Platinum-Ineligible Patients With Unresectable, Stage IV Urothelial Carcinoma
Presented by Jonathan E. Rosenberg, MD
In an oral abstract presentation on the second day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022 Dr. Rosenberg presented results of BAYOU, examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma.
Read More
ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
Presented by Simon J. Crabb, PhD, MBBS
Dr. Crabb presented results of the rucaparib arm of the ATLANTIS trial among patients with metastatic urothelial carcinoma (mUC). The authors postulated that switch maintenance with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib would improve outcomes for patients who had derived benefit from PBC.
Read More
ASCO GU 2022: Meet-URO12 Phase II Study of Niraparib Plus Best Supportive Care vs BSC Alone As Maintenance Treatment in Advanced Urothelial Carcinoma Patients Whose Disease Did Not Progress After First-Line Platinum-Based Chemotherapy
Presented by Francesca Vignani, MD
Dr. Vignani presented results of the Meet-URO12 trial examining niraparib as maintenance therapy in advanced urothelial carcinoma. The authors hypothesized that maintenance treatment with niraparib would improve outcomes among patients who have objective response or stable disease to first line chemotherapy. Read More
ASCO GU 2022: Analysis of Disease-Free Survival in CheckMate 274 by PD-L1 Combined Positive Score and Tumor Proportion Score
Presented by Matt D. Galsky MD, FASCO
Dr. Galsky presented an analysis of the CheckMate274 trial of adjuvant nivolumab in urothelial carcinoma. To better understand the relationship between PD-L1 expression and the efficacy of nivolumab in this space, the authors undertook an analysis of DFS based on PD-L1 expression in both tumor and immune cells using the combined positive score.
Read More
ASCO GU 2022: Primary Analysis From DS8201-a-U105: A Phase 1b, 2-Part, Open-Label Study of Trastuzumab Deruxtecan (T-DXd) With Nivolumab in Patients With HER2-Expressing Urothelial Carcinoma
Presented by Matt D. Galsky, FASCO, MD
Dr. Galsky and colleagues presented results of the DS8201-A-U105 trial of trastuzumab deruxtecan (T-DXd) with nivolumab in patients with HER2-expressing urothelial carcinoma (UC). The authors performed a phase 1b, 2-part, open-label, multicenter study of T-DXd in combination with nivo in pts with HER2-expressing advanced/metastatic UC. Read More
ASCO GU 2022: Impact of PD-L1 Expression on Conventional Urothelial Bladder Carcinoma Genomic Alteration Profile
Presented by Petros Grivas MD, PhD
Dr. Grivas presented a poster examining the effect of PD-L1 expression, as determined by immunohistochemistry (IHC), on genomic alteration profiles in patients with urothelial bladder carcinoma (UBC). Read More
ASTRO 2021: Controversies in the Management of Muscle-Invasive Bladder Cancer
Presented by Alejandro Berlin, MD MSc
In the Latin America ASTRO session of the American Society for Radiation Oncology (ASTRO) Annual Congress, Dr. Berlin presented on controversies in the management of patients with Muscle-invasive bladder cancer (MIBC).
Read More
ESMO 2021: New Developments in Muscle-Invasive Bladder Cancer
Presented by Ronald de Wit, MD, Ph.D.
As a portion of the ESMO Annual Congress, an Educational Session focused on improving outcomes in bladder cancer was held. In this context, Dr. de Wit discussed new developments in muscle-invasive disease.Dr. de Wit began by highlighting the role of chemotherapy as it evolved through the 1980s and 1990s, utilizing a cisplatin backbone in various combinations.
Read More
AUA 2021: State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm
Presented by Cora Sternberg, MD, FACP
In this rapid review for the American Urologic Association (AUA) plenary session, Dr. Cora Sternberg summarized the current status of first and second-line therapy for advanced and metastatic urothelial cancer – while also touching on changes that are upcoming.
Read More
EAU 2021: Predictive Markers for Response in Urothelial Cancer: Are We There Yet?
Presented by Thomas Powles, MD, MBBS, MRCP
In this presentation during the thematic session at the 2021 European Association of Urology (EAU) annual meeting, focusing on immunotherapy in urothelial cancer, Dr. Thomas Powles reviews predictive markers for response in urothelial cancer.
Read More
EAU 2021: Circulating Tumor Cell-Driven Use of Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: Final Results of the CirGuidance Study
Presented by Nick Beije, MD, Ph.D and Morgan Roupret, MD, Ph.D
Dr. Nick Beije of Rotterdam, presented the final results of the CirGuidance Study, which focused on the use of the circulating tumor cells (CTCs) to drive neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). This was followed by a discussion and summary from Dr. Morgan Roupret.
Read More
ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?
Presented by Shilpa Gupta, MD
Previous studies have suggested that gemcitabine-cisplatin + drug X is not better than gemcitabine-cisplatin alone in phase 3 trials to date. This includes the EORTC 30987 trial assessing gemcitabine-cisplatin + paclitaxel versus gemcitabine-cisplatin and the recently published CALGB 90601 trial assessing gemcitabine-cisplatin + bevacizumab versus gemcitabine-cisplatin + placebo.
Read More
ASCO 2021: Novel Immunotherapy Approaches Across the Spectrum of Urothelial Cancer Stages
Presented by Bishoy M. Faltas, MD
The bladder cancer poster discussion session at American Society of Clinical Oncology (ASCO) 2021 featured a discussant presentation by Dr. Bishoy Faltas examining novel immunotherapy approaches across the spectrum of urothelial cancer stages.
Read More
Biomarkers, Immunotherapy and Future Directions
Presented by Jason Efstathiou, MD, DPhil
Closing this course on TMT, Dr. Efstathiou presented on Biomarkers, Immunotherapy and Future Directions in TMT. He began by emphasizing, as many of the prior presentations in the course had done, that clinical-pathologic features affect TMT decisions, including tumor size, T stage, hydronephrosis, renal function, and bladder function. The question then is whether genomic factors may be able to inform bladder sparing therapy.
Read More
SES AUA 2021: Modern Bladder Cancer Warfare: Does "Leave No Bladder Behind" Ethos Still Apply?
Presented by Alex Kutikov, MD, FACS
The State of the Art lecture at the 2021 virtual annual meeting of the Southeastern Section of the AUA was provided by Dr. Alex Kutikov who discussed the current applications for radical cystectomy and perhaps to spare certain bladders while minimizing risk of disease progression.
Read More
SES AUA 2021: Avelumab First-Line Maintenance + Best Supportive Care (BSC) vs BSC Alone with 1L Chemotherapy for Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analyses
Presented by Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial.
Read More
ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma
Presented by Dean F. Bajorin, MD
For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone.
Read More
ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion
Presented by Arlene O. Siefker-Radtke, MD
In this presentation, Arlene O. Siefker-Radtke, MD provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. Primary results of EV-301 and EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
Read More
ASCO GU 2021: SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan, and Sacituzumab Govitecan plus Pembro Before Radical Cystectomy, for Patients with MIBC Who Cannot Receive or Refuse Cisplatin-Based Chemotherapy
Presented by Andrea Necchi, MD
Muscle-invasive bladder cancer is a systemic disease as >40% of patients ultimately develop recurrence after radical cystectomy. For patients who cannot receive or refuse cisplatin-based chemotherapy, there is no standard-of-care neoadjuvant therapy.
Read More
ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Presented by Thomas Powles, MBBS, MRCP, MD
Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Up to 50% of these patients are medically ineligible for cisplatin due to low performance status, renal dysfunction, or other medical comorbidities.
Read More
ASCO GU 2021: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analysis Based On Duration And Cycles Of First-Line Chemotherapy
Presented by Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial.
Read More
ASCO GU 2021: TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic Or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy
Presented by Petros Grivas, MD, Ph.D.
In a presentation at the 2021 ASCO GU, Dr. Grivas described the design of the confirmatory phase III trial, TROPiCS-04. TROPiCS-04 is a global, multicenter, open-label, randomized controlled trial, performed among patients with locally advanced unresectable or metastatic urothelial carcinoma.
Read More
SUO 2020: Navigating Novelty in Advanced Disease: Current Evidence and Adaptive Strategies for Sequencing Immune Checkpoint Inhibitors, FGFR Inhibitors, and Antibody-Drug Conjugates
Presented by Neal Shore, MD, FACS, and Robert Dreicer, MD
At the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting, Dr. Neal Shore chaired a session examining the use of newer and emerging agents in bladder cancer, which highlighted a presentation by medical oncologist Dr. Robert Dreicer discussing novel treatment options for patients with advanced bladder cancer.
Read More
EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer
Presented by Andrea Necchi, MD,
In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer.
Read More
EMUC 2020: Optimal First Line Therapy in Metastatic Bladder Cancer Disease
Presented by Matthew Galsky, MD
In an oral presentation in the Refining the Treatment of Bladder Cancer session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Matthew
Glasky presented an overview of optimal first-line approaches to the treatment of metastatic bladder cancer. Dr. Galsky began by highlighting the treatment approach in what he called the “not too distant past:
Read More
ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer
Presented by Michiel S. van der Heijden, MD, PhD
Platinum-based chemotherapy is the mainstay of first-line treatment for medically eligible patients with advanced urothelial carcinoma (UC). Unfortunately, up to 50% of patients are unable to receive cisplatin, and disease progression often develops even for patients who receive cisplatin.
Read More
ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitors
Presented by Yohann Loriot, MD, MSc
Treatment options for advanced urothelial cancer that has progressed through platinum chemotherapy and immune checkpoint blockade consist of (1) single agent chemotherapy, (2) FGFR inhibitor therapy
for tumors harboring susceptible alterations, and (3) the antibody-drug conjugate enfortumab vedotin.
Read More
ESMO Virtual Congress 2020: Patient-Reported Outcomes from JAVELIN Bladder 100: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma
Presented by Thomas B. Powles, MBBS, MRCP, MD
Urothelial carcinoma has a substantial impact on patient qualify of life. Patients may experience a multitude of disease-related symptoms, including pain, urinary frequency, physical changes, and mental health issues, with all affect quality of life.
Read More
ESMO Virtual Congress 2020: Subgroup Analyses from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + Best Supportive Care (BSC) vs BSC Alone with 1L Chemotherapy for Advanced Urothelial Carcinoma
Presented by Petros Grivas, MD, Ph.D.
Advanced urothelial carcinoma has among the worst prognosis for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy.
Read More
SUO - AUA 2020 Summer Webcast: Identical, Fraternal or Disparate Twins? The Case of Bladder Urothelial Carcinoma and Upper Tract Urothelial Carcinoma
Presented by Bishoy M. Faltas, MD
(UroToday.com) At the Society of Urologic Oncology (SUO) Summer Virtual Webcast, Bishoy Faltas, MD, from Weill Cornell compared the genetic components of the bladder and upper tract urothelial carcinoma. Upper tract urothelial carcinoma comprises 5-10% of all urothelial carcinomas with a unique epidemiologic association with Arsenic exposure and aristolochic acid.
Read More
EAU 2020: Novel Urothelial Cancer Treatment Beyond PD-1/PD-L1 Inhibition
Presented by Yohann Loriot, MD, PhD
(UroToday.com) Outcomes of immunotherapy have been the highlight of meetings over the last decade. At the 2020 European Association of Urology (EAU) Virtual Meeting, Yohann Loriot, MD, PhD, discussed novel treatment options beyond immunotherapy. As noted by Dr. Loriot, the vast majority of trials with new drugs are investigating immunotherapy, but a better understanding of the tumor biology is identifying new targets.
Read More
ASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease
Presented by Cora N. Sternberg, MD, FACP
San Francisco, California (UroToday.com) To close the session entitled “Risk stratification and management of high-risk muscle invasive urothelial carcinoma,” Cora N. Sternberg
Read More
ASCO GU 2020: Options for Bacillus Calmette-Guérin (BCG) Refractory Disease
Presented by Wassim Kassouf, MD, FRCS
San Francisco, California (UroToday.com) Treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) remains a significant
Read More
ASCO GU 2020: Study EV-103: Preliminary Durability Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Presented by Jonathan E. Rosenberg, MD
San Francisco, CA (UroToday.com) There are limited effective treatments for patients with metastatic bladder cancer who are platinum ineligible. Single-agent immunotherapy
Read More
SUO 2019: Immunotherapy in Bladder Cancer: Targets and Surgical Timing
Presented by Karen M. Wheeler, MD
Washington, DC (UroToday.com) As part of the Research Scholars Update at the 20th Annual Meeting of the Society of Urologic Oncology, Dr. Karen Wheeler presented her work on
Read More
SUO 2019: Organ Preservation in Urologic Cancers - Muscle-Invasive Bladder Cancer
Presented by Robert Huddart, MA, MBBS, MRCP, FRCR
Washington, DC (UroToday.com) Organ preservation in bladder cancer has been a widely debated topic with polarizing views from different centers and researchers worldwide.
Read More
SIU 2019: Debate - Chemotherapy is Better than Immunotherapy as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
Presented by Roland Seiler, PhD
Athens, Greece (UroToday.com) Dr. Roland Seiler presented after
Dr. Andrea Necchi, supporting the role of chemotherapy in the neoadjuvant setting of treating muscle invasive bladder cancer
Read More
SIU 2019: pT0 after Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Carcinoma of the Bladder: Implications for Bladder Preservation
Presented by Kelly Stratton, MD
Athens, Greece (Urotoday.com) Neoadjuvant chemotherapy (NAC) in bladder cancer has been proven to improve overall survival in patients with muscle-invasive bladder cancer
Read More
IBCN 2019: Genomic Classifier to Predict Luminal Bladder Tumors
Presented by Joep J. de Jong
Aarhus, Denmark (UroToday.com) Joep J. de Jong from the Erasmus MC Cancer Institute in Rotterdam discussed efforts at developing a genomic classifier to predict clinically
Read More
ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma
Presented by Thomas Powles, MBBS
Barcelona, Spain (UroToday.com) Atezolizumab has received regulatory approval for patients with locally advanced or metastatic urothelial carcinoma.
Read More
ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Presented by Enrique Grande, MD
Barcelona, Spain (UroToday.com) First-line metastatic urothelial carcinoma treatment includes cisplatin or carboplatin-based chemotherapy or checkpoint inhibitors, depending on patient eligibility and PD-L1 status.
Read More
ESMO 2019: Phase 2 TROPHY-U-01 Open-Label Study of Patients Receiving Sacituzumab Govitecan with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or Immunotherapy
Presented by Scott T. Tagawa, MD, MS
Barcelona, Spain (UroToday.com) Platinum-based chemotherapy has been the standard first-line therapy for patients with metastatic urothelial cancer (mUC). Historically, response to standard of care second-line chemotherapy regimens is < 15%.
Read More
ESMO 2019: EV-103: Initial Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Presented by Christopher J. Hoimes, DO
Barcelona, Spain (UroToday.com) Platinum-based chemotherapy remains the standard of care for patients with locally advanced or metastatic urothelial carcinoma. Despite the use of first-line PD-1/PD-1L inhibitors, 71–76% of patients who are cisplatin-ineligible do not respond to treatment.
Read More
ASCO 2019: EV-201: Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Platinum and Immune Checkpoint Inhibitors - Medical Oncologist Perspective
Presented by Daniel Peter Petrylak, MD
Chicago, IL (UroToday.com) After cisplatin-based chemotherapy and immune checkpoint inhibitors, there exist a paucity of effective therapies for patients with metastatic urothelial carcinoma (mUC). Enfortumab vedotin (EV) is an antibody-drug
Read More
ASCO 2019: FIERCE-22: Clinical Activity of Vofatamab - FGFR3 Selective Inhibitor in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma - Medical Oncologist Perspective
Presented by Arlene O. Siefker-Radtke, MD
Chicago, IL (UroToday.com) FGF receptor 3 (FGFR3) alterations are frequently encountered in urothelial carcinoma, both in non-muscle invasive and muscle-invasive disease.
1 For patients with muscle-invasive disease, FGFR3 mutations have been observed in 2% of primary tumors and 9% of metastases.
2 Read More
ASCO 2019: Phase II Study of Nivolumab and Ipilimumab for Advanced Bladder Cancer of Variant Histologies - Medical Oncologist Perspective
Presented by Bradley Alexander McGregor, MD
Chicago, IL (UroToday.com) Combination ipilimumab/nivolumab (ipi/nivo) has seen success in melanoma, MSI high colorectal cancer, and renal cell carcinoma (RCC).
1 In urothelial carcinoma, CheckMate 032 evaluated the efficacy of ipi/nivo in an open-label, multicenter, phase I/II
Read More
ASCO 2019: A Phase II Study of RC48-ADC in HER2-Positive Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Medical Oncologist Perspective
Presented by Xinan Sheng, MD
Antibody-drug conjugates (ADCs) have made significant progress in several tumor types over the past few years, including brentuximab vedotin for Hodgkin lymphoma, TDM1 for breast cancer, and inotuzumab ozogamicin for non-Hodgkin lymphoma.
1 Linking a targeted monoclonal
Read More